Introducing next-generation RNase inhibitors - ideal for single-cell and in situ RNA-sequencing
SEQURNA's RNase inhibitor makes RNA work and sequencing pipelines more accessible, affordable, and sustainable. Unlike competitors’ recombinant RNase inhibitors, the SEQURNA inhibitor is thermostable and can be shipped and stored at room temperature without affecting performance. These features not only simplify shipping and storage logistics, eliminate batch effects, and reduce costs for the user but also enable new and simplified workflows and novel laboratory protocols, including heat cycles.
Propel your biotech business or research, and choose a more environmentally sustainable option for RNase inhibition in your RNA-seq workflows, by becoming an early user of SEQURNA’s RNase inhibitor. Our R&D team is keen to assist and advice in the transition.
Find out more at www.sequrna.com or email us at info@sequrna.com
Company Details
- Employees
- 4
- Founded
- -
- Address
- Nanna Svartz Vag 4, Solna 0,171 65,sweden
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.sequrna.com
- Keywords
- Single-Cell sequencing, In-situ sequencing, RNA research, RNA, PCR, Thermostability, Sustainability.
- HQ
- SOLNA 0
Sequrna Questions
Sequrna's website is http://www.sequrna.com
Sequrna's LinkedIn profile is https://se.linkedin.com/company/sequrna
Sequrna has
4 employees.
View email and phone details for 4
employees at Sequrna.
Sequrna's industry is
Biotechnology Research
Sequrna's top competitors are
Epigenica,
Xpress Genomics,
Aax Biotech Ab,
Basic Genomics Ab,
Genovis,
Ciprocity,
Moltic Pharma,
Alligator Bioscience Ab,
Molecular Attraction Ab,
Nexus Epigenomics.
Sequrna's categories are Biotechnology Research
Sequrna's founding year is 2022
